



**Distribution:** As Appendix 1

**From:** Chief Pharmaceutical Officer, Andrew Evans

**Date:** 15 June 2021

**Reference:** CEM/CPhA/2021/15

**Category:** Immediate – Action within 24 hours

**Title:** Covid-19 Therapeutic Alert: Remdesivir for patients hospitalised with COVID-19 (adults and children aged 12 years and older)

*This guidance updates and replaces the COVID-19 Therapeutic Alert CEM//CPhA/2020/50a, which was published on 9 November 2020.*

**For Action and information by:**

- Chief Pharmacists
- Medical Directors

**Issue:**

Remdesivir has been available to UK clinicians treating hospitalised patients with COVID-19 since May 2020.

The UK interim clinical commissioning policy has been updated to allow an extended treatment duration and other exemptions for immunocompromised patients, clarify when a further treatment course might be given following readmission, and reflect exceptions in the eligibility criteria for patients with end-stage renal disease on haemodialysis.

The attached therapeutic alert and revised policy document provide further detail and highlight required actions:

- DHSC COVID-19 Therapeutic Alert CEM/CMO/2021/013
- Remdesivir May 2021 updated policy

**Send to:**

Chief Executives of Health Boards  
Medical Directors of Health Boards  
Nurse Directors Health Boards  
Directors of Public Health  
Health Board Chief Pharmacists  
Hospital Chief Pharmacists  
PHW Consultants in Pharmaceutical Public Health  
Chief Executives of NHS Trusts  
Principal Pharmacist Welsh Quality Control  
Principal Pharmacist Welsh Medicines Information Centre  
AWTTC  
NHS Direct

**Welsh Government:**

Chief Medical Officer  
Chief Nursing Officer  
Chief Scientific Officer  
Director General Health and Social Services Group  
Emergency Planning Adviser  
Deputy Director Primary Care  
Director Primary Care & Innovation  
HSSG Comms  
NHS Procurement Specialists